Table 3. Incidence of rejection.
| RTX-KTx | C-KTx | ||
|---|---|---|---|
| N | 115 | 115 | P |
| BPAR free ratio (%) | .041 | ||
| 1 year | 96.5 | 86.9 | |
| 2 year | 92.1 | 81.7 | |
| 5 year | 88.7 | 78.2 | |
| Total (%) | 13 (11.3) | 25 (21.7) | .033 |
| AABMR | 2 | 6 | .499* |
| CABMR | 6 | 5 | 1* |
| TCMR | 3 | 11 | .018* |
| IA | 0 | 4 | |
| IB | 1 | 1 | |
| IIA | 2 | 3 | |
| IIB | 0 | 3 | |
| Mixed type rejection | 2 | 3 | 1* |
| AABMR+TCMR | 1 | 1 | |
| CABMR+TCMR | 1 | 2 | |
| Histopathological scores | |||
| i+t | 2.3±1.9 | 2.3±1.9 | .658* |
| v | 0.2±0.4 | 0.5±0.7 | .436* |
| g+ptc | 2.9±1.26 | 2.1±1.5 | .225* |
| ci+ct | 1.9±1.5 | 0.9±1.2 | .088* |
| cg | 0.6±1.0 | 0.2±0.4 | .225* |
| cv | 0 | 0.1±0.4 | 1* |
| c4d | 1.2±0.9 | 0.8±1.0 | .610* |
* Fisher’s exact test
BPAR, biopsy-proven acute rejection; AABMR, acute antibody-mediated rejection; CABMR, chronic antibody-mediated rejection; TCMR, T cell-mediated rejection